Babson Diagnostics

Babson Diagnostics

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $44.7M

Overview

Babson Diagnostics is a private, pre-revenue company developing a novel platform for convenient, capillary-based blood collection and diagnostic testing. Founded in 2017 and based in Austin, Texas, the company's technology is designed to enable high-quality, FDA-cleared blood tests using a small sample from a fingerstick, performed by retail pharmacy staff. This approach targets the significant market for routine health monitoring, aiming to reduce barriers to testing and improve preventative care. Babson is positioned as a diagnostics service provider, building a network of accessible testing locations.

General Health MonitoringPreventative Care

Technology Platform

Integrated system for convenient, standardized capillary blood collection, sample stabilization, and laboratory analysis designed for use in retail settings.

Funding History

2
Total raised:$44.7M
Series B$31M
Series A$13.7M

Opportunities

The massive, growing market for routine blood testing is hampered by patient inconvenience.
Babson's retail pharmacy-based model taps into the trend of accessible care and can capture non-compliant patients.
Partnerships with large pharmacy chains offer a rapid path to scale and consumer trust.

Risk Factors

Key risks include navigating complex FDA regulatory pathways for its collection system, securing insurance reimbursement for a novel collection method, and executing flawlessly within busy retail environments.
It must also prove its capillary sample quality matches the venous draw gold standard.

Competitive Landscape

Competition includes large national laboratories (Quest, LabCorp) with their own retail draw sites and at-home kits, other startups targeting convenient blood collection, and direct-to-consumer testing companies. Babson's differentiation is its focus on integrating a standardized, high-quality service into existing retail pharmacy workflows.